Pacific Biosciences of California Inc - Company Profile
Powered by 
All the sales intelligence you need on Pacific Biosciences of California Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Pacific Biosciences of California Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Pacific Biosciences of California Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Pacific Biosciences of California Inc (Pacific Biosciences) is a life science technology company that designs, develops, and manufactures sequencing solutions. The company's main activities include providing sequencing systems that offer comprehensive views of genomes, transcriptomes, and epigenomes. Its major products include sequencing instruments, Single Molecule, Real-Time (SMRT) Cells, and reagents, which are used in its proprietary SMRT sequencing technology. Pacific Biosciences' products find application in human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It caters to academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company has subsidiaries in the US, Canada, Japan, Germany, China, Singapore, and the UK. Pacific Biosciences is headquartered in Menlo Park, California, the US.
Headquarters
United States of America
Address
1305 O'Brien Drive, Menlo Park, California, 94025
Website
www.pacb.com
Telephone
1 650 5218000
No of Employees
575
Industry
Medical Equipment
Ticker Symbol & Exchange
PACB (NASD)
Revenue (2024)
$160.0M
3.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2025)
XYZ
-76.3%
(2025 vs 2024)
Market Cap*
$397.6M
Net Profit Margin (2025)
XYZ
-69.7%
(2025 vs 2024)
* As of and is in US$
Pacific Biosciences of California Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Sample preparation: | PacBio Certified Service Provider Program | Pacific Biosciences |
| Nanobind kits | Sequencing Methods: | PacBio |
| SRE kits | Whole Genome Sequencing | PureTarget |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In February, PacBio signed a partnership with DNAstack to support first global federated dataset of HiFi whole genome sequencing data. |
| 2026 | New Products/Services | In January, the company unveiled CiFi. |
| 2026 | Plans/Strategy | In January, the company announced plans to collaborate with the n-Lorem Foundation and EspeRare to support the development of individualized antisense oligonucleotide therapies for ultra-rare genetic diseases. |
Competitor Comparison
| Key Parameters | Pacific Biosciences of California Inc | Thermo Fisher Scientific Inc | Agilent Technologies Inc | 10X Genomics Inc | BGI Genomics Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | China |
| City | Menlo Park | Waltham | Santa Clara | Pleasanton | Shenzhen |
| State/Province | California | Massachusetts | California | California | Guangdong |
| No. of Employees | 575 | 125,000 | 17,900 | 1,178 | 3,702 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John F. Milligan, Ph.D. | Chairman | Executive Board | 2020 | 65 |
| Christian O. Henry | Chief Executive Officer; Director; President | Executive Board | 2024 | 58 |
| Jim Gibson | Chief Financial Officer; Principal Accounting Officer | Senior Management | 2026 | 57 |
| Mark Van Oene | Chief Operating Officer | Senior Management | 2021 | 53 |
| Natalie Welch | Chief People Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer